Clinical Trials for Skin Cancer

201804077

An open-label, non-randomized, multi-arm, phase II trial to evaluate the efficacy of pembrolizumab combined with cetuximab in patients with recurrent/ metastatic head and neck squamous cell carcinoma (HNSCC) Phase II Principal Investigator Adkins, Douglas Disease…

201812031

STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial Phase III Principal Investigator Ansstas, George Disease Site Other Skin Learn more about this study at: clinicaltrials.gov

201902130

A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA Phase II Principal Investigator Ansstas, George Disease Site Melanoma, Skin Learn more about this study at:…

201903162

Phase II Study of Optune Device – TT Fields plus Nivolumab and Ipilimumab for Melanoma with Brain Metastasis Phase II Principal Investigator Ansstas, George Disease Site Melanoma, Skin Learn more about this study at: clinicaltrials.gov

201904155

A phase 1b/2a, open label study to evaluate anti-tumor efficacy and safety of rhIL-7-hyFc (NT-I7) in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory high-risk skin cancers Phase I/II Principal Investigator Ansstas,…

201905156

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma Phase III Principal Investigator Ansstas, George Disease Site Other Skin Learn…

202003124

Adjuvant pembrolizumab and hypofractionated radiation therapy for the treatment of mucosal melanoma Phase II Principal Investigator Ansstas, George Disease Site Melanoma, Skin Learn more about this study at: clinicaltrials.gov

202008099

A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) Phase III (Cancer Control) Principal…

202011137

A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF BELVARAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH EITHER COBIMETINIB OR COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH NRAS-MUTANT ADVANCED MELANOMA…

202103077

Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF-mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy Phase I/II Principal Investigator Johanns, Tanner Disease Site…

202103081

Phase 2 Study of FLX475 in Combination with Ipilimumab in Advanced Melanoma Phase II Principal Investigator Johanns, Tanner Disease Site Melanoma, Skin Learn more about this study at: clinicaltrials.gov